Loading
Latest filing published 07 May 2026 for HighTide Therapeutics, Inc. - B.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
YU Meng is a declared insider of HighTide Therapeutics, Inc. - B (chief executive), with filings sourced from HKEX. In total, 8 filings cover trades dated from 22 December 2023 to 30 April 2026.
Every open-market trade on record is a sale: 1 sale. The amount is not disclosed for 1 filing. In 2026 alone, the filings show no purchases and 1 sale.
On 7 May 2026 came the latest disclosure, an open-market sale in HighTide Therapeutics, Inc. - B. Filings reach the HKEX feed a median of 8 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.